Search Results

Dr. Robert A. Harrington, a cardiologist and the Arthur L. Bloomfield Professor of Medicine and chair of the Department of Medicine at Stanford University, has been named the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University.

The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases.

BriaCell Therapeutics Corp. announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties’ plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell’s novel immunotherapy, Bria-IMT™.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the launch of the Spatial Atlas of Human Anatomy initiative, in collaboration with Weill Cornell Medicine, to create multicellular, single-cell, and sub-cellular maps of 30 non-diseased organs from a healthy and diverse population of adults.

US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza International Trials Unit lacted in the Lake Zone of Tanzania with the aim of exploring the burden of arrhythmia in adults with and without HIV.

Applied DNA Sciences, Inc. and the Cornell University College of Veterinary Medicine announced the signing of a sponsored research agreement for a translational research study to accelerate the development and optimization of the Company’s LineaDNA™-lipid nano particle -based veterinary vaccine platform for veterinary diseases.

Albert Einstein College of Medicine has appointed nationally recognized education leader Yoon Kang, M.D., as its inaugural vice dean for education, following a national search.

Seer, Inc. today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer’s Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines.

Kazia Therapeutics Limited is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatment of newly diagnosed and recurrent glioblastoma, has been initiated at Weill Cornell Medicine, with the first patient successfully initiated in the study and a second patient already in screening.